INTRODUCTION
============

Although obesity is a well-known risk factor for type 2 diabetes mellitus (T2DM), many recent studies have focused on subgroups that show a non-linear relationship between body mass index (BMI) and adverse clinical outcome, such as metabolically healthy obese (MHO) and metabolically unhealthy normal weight (MUNW) phenotypes. In a previous study, the prevalence of MHO individuals ranged from 3.3% to 43.0% in Caucasian populations, and 11.9% to 49.0% in Asian populations \[[@B1]\]. The MHO individuals were characterized by preserved insulin sensitivity, low visceral fat accumulation, low inflammatory activity, and a lack of metabolic and cardiovascular complications \[[@B2]\]. Nevertheless, there have been conflicting studies regarding the MHO phenotype on the development of T2DM and cardiovascular disease (CVD) \[[@B3][@B4]\]. These inconsistent outcomes are partly due to the lack of consensus on the definition of metabolic abnormality and changes in body size and metabolic phenotype during the follow-up period \[[@B5][@B6][@B7]\]. Recently, large cohort studies have demonstrated that the MHO status represents a transient condition which involves a temporal expression of the dynamics in continuous variables \[[@B8]\]. In the Nurses\' Health Study (NHS), during the median follow-up of 24 years, a substantial percentage of metabolically healthy women converted to unhealthy phenotypes (84% of women with obesity and 68% women with normal weight) \[[@B9]\]. From the 6,809 subjects of the Multi-Ethnic Study of Atherosclerosis (MESA), almost half of the baseline MHO group progressed to a metabolically unhealthy status during the 12.2-year follow-up; this group also exhibited an increased risk of CVD compared to the stable MHO group (odds ratio, 1.60; 95% confidence interval \[CI\], 1.14 to 2.25) \[[@B10]\]. Considering that the clinical meaning of the MHO phenotype becomes more critical during a longer follow-up period \[[@B11]\], the MHO phenotype is regarded as an intermediate stage between a healthy, normal weight and unhealthy, obese individuals.

Metabolic health is also recognized as a transient phenotype among normal weight individuals. In the NHS, only 15% of normal weight women remained metabolically healthy after 30 years of follow-up \[[@B9]\]. MUNW subjects exhibited significantly increased risks of T2DM and CVD \[[@B3][@B12]\]. One of the underlying mechanisms that places MUNW individuals at a higher metabolic risk includes the predominant visceral and ectopic fat accumulation relative to BMI \[[@B13]\]. Therefore, in order to identify individuals with an increased risk of T2DM, continuous assessment for metabolic risk should be monitored both in normal weight and obese subjects.

In the present study, in order to analyze the effect of the dynamic transition of metabolic health status on the incidence of T2DM both in obese and normal weight individuals, we classified subjects into four groups as follows: (1) stable metabolically healthy normal weight (MHNW) individuals, who maintained a metabolically healthy phenotype; (2) unstable MHNW, who changed into metabolically unhealthy phenotype; (3) stable MHO; and (4) unstable MHO. We then compared the relative risk (RR) of T2DM during 4.03 years of follow-up using the large-scale Korean National Health Insurance Service (NHIS) database.

METHODS
=======

Data source and study population
--------------------------------

The data was obtained from the NHIS and was recorded from January 2009 to December 2017. The NHIS covers almost the entire Korean population (97%) and recommends that all registered people receive a health check-up every 1 or 2 years. The NHIS provides a socioeconomic database (e.g., age, sex, and income), a health exam database (e.g., height, weight, and laboratory variables), claims for the disease diagnosis codes of the International Classification of Diseases (ICD-10), and the hospital utilization database. Further details of this database, including validity, have been described in a previous report \[[@B14]\]. Our study protocol was approved by the Korea University Institutional Review Board (IRB), and was in accordance with the Declaration of Helsinki of the World Medical Association (2019GR0106). An informed consent exemption was granted by the IRB since, for the purposes of this study, only anonymous and de-identified information was provided by the NHIS.

In this retrospective longitudinal study, we enrolled 7,523,971 participants aged ≥20 years who underwent a health exam between 2009 and 2010 and had another health exam after 4 years. We excluded subjects who met the following criteria: (1) defined a metabolically unhealthy at baseline (*n*=2,059,916); (2) claims of T2DM, stroke, myocardial infarction, congestive heart failure, and total or partial pancreatectomy (*n*=329,870); and (3) missing data (*n*=1,654,671) ([Fig. 1](#F1){ref-type="fig"}). As a result, a total of 3,479,514 subjects were enrolled in the final analysis. The primary outcome in the present study was the development of T2DM during the median 4.03-year (interquartile range, 3.34 to 4.42) follow-up duration. The study population was followed from baseline until the date of death, development of T2DM, or December 31, 2017, whichever came first.

Definitions
-----------

T2DM was defined as at least one claim per year for the prescription of anti-diabetes medication or a fasting glucose level ≥126 mg/dL under ICD-10 codes (E11--14). Subjects who had claims under ICD-10 code E10 were excluded in order to rule out the possibility of type 1 diabetes. Hypertension was defined as systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥80 mm Hg, or the presence of claims of anti-hypertensive medications under ICD-10 codes I10--13, 15. Dyslipidemia was defined as total cholesterol level ≥240 mg/dL or the presence of claims of anti-hyperlipidemic medications under ICD-10 code E78. Myocardial infarction was defined as a claim of ICD I21--22 at least twice, or once if hospitalization occurred. Ischemic stroke was defined as a claim of ICD I63--64 with hospitalization and a claim for brain imaging modalities. Heart failure was defined as at least one hospitalization under ICD-10 code I50. Alcohol consumption was defined as drinking more than 30 g of alcohol per day, and current smoker was defined according to the questionnaire. Regular exercise was defined as moderate intensity physical activity for more than 30 minutes at least 5 days a week, and high intensity physical activity for more than 20 minutes at least 3 days a week. A low income level was defined from registration in the Medical Aid program as the lowest income population or the lowest one-fifth of the rest of the population in the National Health Insurance program based on monthly household income. The plasma glucose level and lipid profiles were measured from venous samples obtained after an overnight fast. These health check-ups were only carried out at hospitals that were certified by the NHIS.

Body phenotype and metabolic status
-----------------------------------

The body size and metabolic status were examined at baseline and follow-up. The BMI was calculated as weight (kg) divided by height squared (m^2^), and normal weight was defined as a BMI of 18 to 25 kg/m^2^, while obesity was defined as a BMI ≥25 kg/m^2^ \[[@B15]\]. Subjects were considered as metabolically unhealthy if they met three or more of the following criteria based on the definition of metabolic syndrome \[[@B16]\]: (1) waist circumference ≥90 cm in men and ≥85 cm in women; (2) SBP ≥130 mm Hg or DBP ≥85 mm Hg or on antihypertensive medication; (3) fasting plasma glucose (FPG) ≥100 mg/dL or claim for T2DM or on anti-diabetic medications; (4) hypertriglyceridemia ≥150 mg/dL or on lipid medications; and (5) high density lipoprotein cholesterol \<40 mg/dL in men and \<50 mg/dL in women, or medication use.

The subjects were stratified into four groups according to baseline body size and whether a metabolically unhealthy phenotype occurred after 4 years: (1) baseline MHNW, maintaining a metabolically healthy phenotype after 4 years (stable MHNW); (2) MHNW with the development of a metabolically unhealthy phenotype (unstable MHNW); (3) MHO, maintaining a metabolically healthy phenotype (stable MHO); and (4) MHO with the development of a metabolically unhealthy phenotype (unstable MHO).

Statistical analysis
--------------------

Data are expressed as mean±standard deviation, median (interquartile range), or number (percentage). The differences between the four groups were assessed by one-way analysis of variance, Kruskal-Wallis *H* test, or chi-square test, and subsequent comparisons were performed by the Bonferroni test. The incidence rate of T2DM was presented as 1,000 person-years. Kaplan-Meier curves were conducted to estimate the cumulative incidence of T2DM and log-rank test was performed to analyze the difference between the four groups. Cox proportional hazards model was used to calculate the hazard ratios (HR) and 95% CI values for the incidence of T2DM according to baseline body size phenotype and metabolically unhealthy exposure: model 1 was unadjusted; model 2 was adjusted for age and sex; model 3 was adjusted for age, sex, smoking, alcohol consumption, regular exercise, and family history of T2DM; model 4 was adjusted for age, sex, smoking, alcohol consumption, regular exercise, family history of T2DM, and mean FPG level, that mean average level of baseline and follow-up FPG values. Sensitivity analyses were also performed in order to exclude subjects with an FPG ≥100 mg/dL from the first to last health examination, or to exclude subjects with cancer (ICD-10 codes C00--C97) either at or before follow-up. Furthermore, adjusted HRs and 95% CIs for the T2DM incidence rate in subjects with unstable MHNW and unstable MHO were compared to those with stable MHNW (reference group) and stable MHO (reference group) in subgroups classified by age (\<65 years vs. ≥65 years), sex, and weight changes between two health check-ups (weight loss \<−5%, −5%≤ weight stable \<5%, weight gain ≥5%), respectively. The stratified analysis and interaction testing were conducted using a likelihood ratio test to assess the potential effect modification by the factors determining the subgroups. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), and *P*\<0.05 were considered as statistically significant.

RESULTS
=======

Baseline characteristics of the study population
------------------------------------------------

The characteristics of the subjects according to baseline body size phenotype and existence with change into a metabolic unhealthy profile during the 4-year follow-up period are presented in [Table 1](#T1){ref-type="table"}. In total 3,479,514 subjects aged over 20 years were enrolled; 2,377,219 (68.3%), 305,924 (8.8%), 545,546 (15.7%), and 250,825 (7.2%) subjects were categorized into the stable MHNW, unstable MHNW, stable MHO, and unstable MHO groups, respectively. The percentage of those that acquired metabolically unhealthy phenotype after 4 years was 11.1% in the MHNW group and 31.5% in the MHO group. According to body size phenotype, the proportion of smoking, alcohol consumption, regular exercise, and family history of diabetes, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) levels were higher in patients with obesity than those with normal weight. Aspects of metabolic change, the unstable group showed a higher prevalence of smoking, alcohol consumption, and family history of diabetes and higher blood pressure, fasting glucose, total cholesterol, triglyceride, low density lipoprotein cholesterol, AST, ALT, and GGT levels than the stable group in both in obese and normal weight subjects. There were significant differences between the four groups in all of the baseline characteristic parameters, with the exception of low-income status (stable MHNW vs. unstable MHO, *P*=0.194).

Risk of incident T2DM according to body size phenotype and metabolic stability
------------------------------------------------------------------------------

During the 13,502,376 person-years, a total of 61,350 subjects developed T2DM. [Fig. 2](#F2){ref-type="fig"} demonstrates the Kaplan-Meyer curves for the cumulative incidence of T2DM for each group. Subjects in the unstable MHO group had the highest probability of developing T2DM, and the probabilities decreased consecutively for the unstable MHNW, stable MHO, and stable MHNW groups (log rank test, *P*\<0.001). The incidence rate (number of events per 1,000 person-years) of T2DM was 2.3 in the stable MHNW group, 12.9 in the unstable MHNW group, 4.4 in the stable MHO group, and 16.5 in the unstable MHO group ([Table 2](#T2){ref-type="table"}). The adjusted HR for the incidence of T2DM was 1.81 (95% CI, 1.76 to 1.85), 3.23 (95% CI, 3.16 to 3.30), and 4.67 (95% CI, 4.58 to 4.77) in the stable MHO, unstable MHNW, and unstable MHO groups respectively, when compared to the stable MHNW group after adjustment for age, sex, smoking, alcohol consumption, regular exercise, family history of T2DM, and mean FPG ([Table 2](#T2){ref-type="table"}). The association between metabolic stability, body size phenotype, and the development of T2DM was not significantly different after excluding subjects with an FPG ≥100 mg/dL ([Supplemental Table S1](#S1){ref-type="supplementary-material"}) or previous history of any cancer ([Supplemental Table S2](#S2){ref-type="supplementary-material"}).

Subgroup analysis
-----------------

We performed stratified analysis and interaction testing to analyze the effect of the transition into a metabolically unhealthy phenotype on the incidence of T2DM according to age, sex, and weight change ([Fig. 3](#F3){ref-type="fig"}, [Supplemental Table S3](#S3){ref-type="supplementary-material"}). We evaluated the HR for the incidence of T2DM in the metabolically unstable group compared to the metabolically stable healthy group in the normal weight and obesity groups, respectively. The effect of the metabolic change on T2DM was more obvious in the normal weight group (HR, 3.11; 95% CI, 3.04 to 3.17) than the obesity group (HR, 2.68; 95% CI, 2.61 to 2.76). Furthermore, the effect of a metabolically unhealthy status on the risk of T2DM was pronounced in individuals aged \<65 years, women, and individuals with weight gain in both normal weight and obese groups ([Fig. 3](#F3){ref-type="fig"}). With regards to the aspect of weight change, increased HR was most profound in individuals with weight gain, followed by individuals with stable weight and those with weight loss (*P* for interaction \<0.001).

DISCUSSION
==========

In this study, the proportion of subjects that developed metabolically unhealthy phenotype after a 4-year follow-up was 11.1% in the MHNW group and 31.5% in the MHO group. Transition into a metabolically unhealthy phenotype significantly increased the risk of T2DM both in obese and normal weight groups. The unstable MHO group exhibited the highest risk of T2DM after adjusting for other confounding factors. Interestingly, the unstable MHNW group had a higher risk of T2DM than the stable MHO group, although the stable MHO subjects also showed an increase in the risk of T2DM.

The unique subgroup of obesity, MHO subjects exhibit a healthy metabolic profile and have reduced CVD risk factors. Recent longitudinal studies have demonstrated that the MHO phenotype is not a completely benign condition. In a meta-analysis including 13 follow-up studies, MHO subjects had higher risk of CVD events than MHNW subjects (pooled RR, 1.45; 95% CI, 1.99 to 2.69) \[[@B17]\] and with respect to T2DM, individuals with MHO had a substantially increased risk of T2DM than MHNW subjects (RR, 4.03; 95% CI, 2.66 to 6.09) \[[@B18]\]. Nowadays, MHO is regarded as a dynamic condition that should be taken into account over time, and the rate of a metabolically unhealthy transition in MHO subjects was increased with the length of follow-up period. In the Whitehall II cohort study during the 20-year period, of a total of 66 MHO adults, 21 (31.8%), 27 (40.9%), and 34 (51.5%) participants transitioned to metabolically unhealthy obesity (MUO) after 5, 10, and 20 years, respectively \[[@B19]\]. Baseline BMI contributes such a change into metabolically unhealthy profiles. Mongraw-Chaffin et al. \[[@B10]\] demonstrated that the cumulative exposure of obesity could increase in cardiometabolic risk. In the present study, stable MHO subjects also had a higher risk of T2DM compared to stable MHNW subjects during the follow-up period, suggesting that obesity itself could increase the risk of T2DM. Therefore, weight reduction in all obese individuals is important for the prevention of T2DM, even in subjects who are metabolically healthy.

Although obesity significantly increases the risk of T2DM, existence with metabolic unhealthiness was a much stronger predictor for incident T2DM than obesity itself. In the present study, the unstable MHO subjects exhibited the highest increased risk for T2DM, while the unstable MHNW subjects also had a higher risk for T2DM than the stable MHO subjects. Previously, Navarro-Gonzalez et al. \[[@B20]\] showed that, among MHO subjects, a greater risk of diabetes was only found in those who progressed to an unhealthier status over time. Furthermore, Liu et al. \[[@B21]\] showed no significant differences in the risk of T2DM between different subjects with different BMI categories with the same number of metabolic abnormalities. A previous meta-analysis, including eight studies, all metabolic unhealthy groups demonstrated a similarly heightened risk of CVD in normal weight (RR, 3.14; 95% CI, 2.36 to 3.93), overweight (RR, 2.70; 95% CI, 2.08 to 3.30), and obese (RR, 2.65; 95% CI, 2.18 to 3.12) groups \[[@B22]\]. These results together with those of the current study suggest that metabolically unhealthiness is more critical to the development of T2DM than obesity, not only in obese but also in normal weighted subjects \[[@B23]\]. In contrast to the conflicting results regarding the MHO phenotype, MUNW individuals had a definite increased risk of cardiometabolic diseases compared to MHNW individuals. We previously reported that the MUNW group had more severe carotid atherosclerosis and a greater risk of death from CVD than the MUO group \[[@B24][@B25]\]. Such a high risk in MUNW individuals is considered to be caused by an unfavorable body fat distribution \[[@B26]\], and the inflammation of visceral adipose tissue and ectopic fat deposition are known to mediate metabolic disturbances regardless of generalized obesity \[[@B13]\]. Asians especially have a relatively substantial portion of visceral adipose tissue and ectopic fat deposition compared to other ethnic populations with similar BMIs, thereby they are especially prone to cardiometabolic diseases in a normal range of weight \[[@B27][@B28]\]. In our study, the RR of T2DM in unstable MHNW subjects compared to stable MHNW subjects (HR, 3.11; 95% CI, 3.04 to 3.47) was greater than that of unstable MHO subjects compared to stable MHO subjects (HR, 2.68; 95% CI, 2.61 to 2.76); this suggests that the influence of the transition to a metabolically unhealthy phenotype on T2DM incidence was more profound in the MHNW group than the MHO group. Hence, in a clinical setting, it is important to focus on individuals with MUNW to make proper intervention to reduce cardiometabolic disorders such as life style modification \[[@B29]\].

In the subgroup analysis, the detrimental effect of the transition to a metabolically unhealthy status on the incidence of T2DM was more prominent in individuals aged \<65 years, women, and subjects with weight gain. Similarly to this result, Kim et al. \[[@B30]\] showed that the long term risk of MHO for the development of T2DM was more prominent in younger patients (aged \<45 years), and in the ATTICA cohort study, MHO status was an independent CVD risk factor only in women \[[@B31]\]. Although the underlying mechanism, that can explain the vulnerability to metabolic risk especially in young adults or women, could not be clarified in the present study, obesity might act as a primary risk for cardiometabolic disorders in women and young adults, whereas additional competing risk factors, such as sarcopenia, low cardio-respiratory fitness, and smoking may play a role in men or elderly individuals \[[@B32]\]. On the other hand, in the unstable MHNW and MHO groups, there was a significantly increased risk for T2DM even in individuals with weight loss; however, the risk considerably increased in subjects with weight gain during the follow-up period (*P* for interaction among groups showing different weight changes \<0.001). These results emphasize the importance of continued weight control, especially before the manifestation of metabolic unhealthy profiles.

The current study had a number of limitations. First, because of the inevitable limitation of our population based cohort study, the definition of T2DM was only based on claim data or the FPG level. Due to the lack of hemoglobin A1c value and the results of the oral glucose tolerance test, the actual prevalence of T2DM may be different from that described in the current study. Second, considering that the criteria of obesity in Asia are different to that of Western countries, these results should be further validated in order to be able to generalize these findings to other ethnic groups. Despite these limitations, this study is the first of its kind to analyze the impact of dynamic transition of metabolic health status on the incidence of T2DM both in obese and normal weight individuals using a large-scale nationwide database that is standardized and validated by the Korean government.

In this nationwide population-based longitudinal cohort study, we found that MHO and MHNW phenotypes were a very transient concept, and that the change into metabolic unhealthiness was an important risk factor for the development of T2DM both in obese and normal weight subjects. Furthermore, although obesity has the potential to increase the risk of T2DM, the transition into a metabolically unhealthy phenotype was a more significant risk factor. Therefore, primary prevention including continuous inhibition from metabolic risk as well as weight management is crucial for reducing the risk of T2DM.

This work was performed in cooperation with the National Health Insurance Service (NHIS). The National Health Information Database constructed by the NHIS was used, and the results do not necessarily represent the opinion of the National Health Insurance Corporation.
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HR and 95% CI for the Incidence of Type 2 Diabetes According to Body Size Phenotype and Metabolic Stability: Sensitivity Analysis Excluding All Subjects with Cancer
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Multivariable Adjusted HR and 95% CI of Type 2 Diabetes in Subgroups in MHNW and MHO Group

![Study flow sheet. CVD, cardiovascular disease.](enm-34-406-g001){#F1}

![Cumulative incidence of type 2 diabetes according to body phenotype and metabolic stability. MHNW, metabolically healthy normal weight; MHO, metabolically healthy obese.](enm-34-406-g002){#F2}

![Hazard ratio (HR) and 95% confidence interval (CI) for the incidence of diabetes according to body weight change in the subjects with unstable metabolically healthy normal weight (MHNW) versus stable MHNW and in the subjects with unstable metabolically healthy obese (MHO) versus stable MHO. The reference group contains subjects who remained metabolically healthy over a 4-year follow-up, stable MHNW and stable MHO.](enm-34-406-g003){#F3}

###### Baseline Characteristics of Subjects According to Body Phenotype and Metabolic Stability

![](enm-34-406-i001)

  Characteristic               Stable MHNW            Unstable MHNW             Stable MHO                Unstable MHO
  ---------------------------- ---------------------- ------------------------- ------------------------- -------------------------
  Number                       2,377,219              305,924                   545,546                   250,825
  Age, yr                      42.45±12.07            49.56±12.40               43.22±11.45               46.00±12.29
  Men                          1,246,808 (52.45)      168,036 (54.93)           383,226 (70.25)           168,953 (67.36)
  Current smoker               584,003 (24.57)        84,545 (27.64)            158,513 (29.06)           79,684 (31.77)
  Alcohol consumption          146,859 (6.18)         26,082 (8.53)             50,597 (9.27)             27,620 (11.01)
  Regular exercise             419,238 (17.64)        59,957 (19.60)            116,658 (21.38)           52,796 (21.05)
  Income (lower 20%)           500,161 (21.04)^a^     69,340 (22.67)            111,059 (20.36)^a^        52,314 (20.86)
  Family history of diabetes   264,493 (11.13)        35,394 (11.57)            66,700 (12.23)            31,649 (12.62)
  Body weight, kg              59.37±8.67             61.55±8.61                74.05±8.90                75.18±10.10
  Body mass index, kg/m^2^     21.76±1.96             22.83±1.60                26.67±1.60                27.21±1.94
  Waist circumference, cm      75.07±6.94             78.85±6.10                85.55±6.02                87.25±6.44
  Systolic BP, mm Hg           117.03±12.96           123.29±13.93              121.65±12.44              124.77±13.25
  Diastolic BP, mm Hg          73.37±9.02             77.10±9.39                76.46±8.85                78.44±9.18
  Fasting glucose, mg/dL       90.42±11.25            93.79±12.47               91.55±11.02               93.09±11.66
  Total cholesterol, mg/dL     187.99±32.61           202.33±36.72              197.55±33.10              204.12±35.65
  Triglyceride, mg/dL          89.06 (89.00--89.11)   122.48 (122.26--122.70)   110.54 (110.40--110.68)   131.32 (131.06--131.57)
  HDL-C, mg/dL                 58.62±16.96            54.47±19.30               54.47±16.32               52.76±17.89
  LDL-C, mg/dL                 111.06±48.20           121.87±48.34              119.79±45.81              123.36±47.39
  ALT, U/L                     18.99 (18.98--19.00)   22.37 (22.33--22.40)      25.83 (25.79--25.86)      28.35 (28.29--28.41)
  AST, U/L                     22.60 (22.59--22.61)   24.48 (24.45--24.51)      25.07 (25.05--25.09)      26.30 (26.26--26.33)
  GGT, U/L                     21.97 (21.96--21.99)   28.39 (28.32--28.46)      30.56 (30.51--30.61)      35.53 (35.44--35.63)

Values are expressed as mean±standard deviation, number (%), or median (interquartile range). There were significant differences between the four groups in all of the baseline characteristic parameters (*P*\<0.001).

MHNW, metabolically healthy normal weight; MHO, metabolically healthy obese; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase.

^a^The results of *post hoc* analysis between the four groups were statistically significant in all of the baseline charatetristics with the exception of low income status (stable MHNW vs. unstable MHO, *P*=0.194).

###### HR (95% CI) for the Incidence of Type 2 Diabetes According to Body Size Phenotype and Metabolic Stability

![](enm-34-406-i002)

  Variable        Total       Events   Follow-up duration, person-yr   Incidence rate, /1,000 person-yr   HR (95% CI)                                                 
  --------------- ----------- -------- ------------------------------- ---------------------------------- ------------------- ------------------- ------------------- -------------------
  Stable MHNW     2,377,219   21,312   9,258,446                       2.30                               1                   1                   1                   1
  Unstable MHNW   305,924     15,071   1,170,674                       12.87                              5.60 (5.48--5.72)   4.33 (4.24--4.43)   4.20 (4.41--4.29)   3.23 (3.16--3.30)
  Stable MHO      545,546     9,274    2,121,322                       4.37                               1.90 (1.85--1.95)   1.77 (1.73--1.81)   1.77 (1.72--1.81)   1.81 (1.76--1.85)
  Unstable MHO    250,825     15,693   951,933                         16.49                              7.19 (7.04--7.34)   6.10 (5.97--6.22)   5.96 (5.84--6.08)   4.67 (4.58--4.77)

Model 1: not adjusted; Model 2: adjusted for age and sex; Model 3: adjusted for model 2 plus smoking, alcohol consumption, regular exercise, and family history of type 2 diabetes; Model 4: adjusted for model 3 plus mean fasting plasma glucose.

HR, hazard ratio; CI, confidence interval; MHNW, metabolically healthy normal weight; MHO, metabolically healthy obese.
